Drug intelligence / Profile preview

CLE-905

Development stage: Preclinical
Lead developer: Syremis Therapeutics
Modality: Small Molecules
Administration: Oral (planned)

Overview

CLE-905 is an investigational small molecule drug developed by Clexio Biosciences. It is a potent and functionally selective dual agonist of the muscarinic acetylcholine M1 and M4 receptors, designed for the treatment of schizophrenia and potentially other psychiatric disorders. The drug aims to address both positive (psychotic) and negative symptoms, as well as cognitive impairment associated with schizophrenia. Preclinical data suggest that its differentiated ADME properties may minimize peripheral exposure, reducing the risk of cholinergic side effects. As of June 2025, it remains in preclinical development with IND-enabling studies ongoing[1][2][3].

Other names: CLE-905CLE905CLE 905

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM4 (M4)

Beyond the preview

Go deeper on CLE-905.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLE-905.

Explore the full profile